Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life

• DOI: 10.1016/j.ctro.2022.04.005
• Publication Date: 2022-04-12T18:25:02Z
• Authors: Sebastian M. Christ; Markus Schettle; Jonas Willmann; Maiwand Ahmadsei; Annina Seiler; David Blum; Matthias Guckenbe...; Nicolaus Andratschke; Caroline Hertler
• Keywords: Performance status

Choosing the right treatment for patient in a setting of metastatic cancer disease remains challenge. To facilitate clinical decision-making, predictive tools have been developed to personalize treatment. Here, we aim assess use recently proposed "METSSS score" as prognostic tool overall survival patients after palliative radiotherapy last phase life.All treated with at end-of-life Department Radiation Oncology University Hospital Zurich between January 2010 and December 2019 were included this study. Data on demographics, diagnosis, comorbidities was extracted from planning electronical medical records system. statistically validity score", mortality risk score calculated, followed by stratification all groups. The prediction 1-year estimates subsequently calculated.Over past decade, 274 received during period. One third female (34%, n = 93). most frequent primary tumor lung (n 121, 44%), 55% 152) had no according Charlson-Deyo comorbidity index. common site brain eye region (42%, 115). median actual 40 days start radiotherapy. model predicted that 269 (98.1%) belong into high-risk, four (1.5%) medium-risk, one (0.4%) low-risk group. 10%.The METSSS correctly our cohort assigning them highest category, it can therefore serve decision-making when symptomatic